MRKR
Marker Therapeutics Inc (MRKR)
Healthcare • NASDAQ • $1.46+1.39%
- Symbol
- MRKR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.46
- Daily Change
- +1.39%
- Market Cap
- $24.34M
- Trailing P/E
- N/A
- Forward P/E
- -7.68
- 52W High
- $4.07
- 52W Low
- $0.81
- Analyst Target
- $7.87
- Dividend Yield
- N/A
- Beta
- 1.43
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Mar…
Company websiteResearch MRKR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.